STOCK TITAN
  1. Home
  2. News
  3. IMRN

Immuron Limited - IMRN STOCK NEWS

Welcome to our dedicated news page for Immuron (Ticker: IMRN), a resource for investors and traders seeking the latest updates and insights on Immuron.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immuron's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immuron's position in the market.

News
Immuron to host Live Virtual Event
Rhea-AI Summary
Immuron (ASX: IMC; NASDAQ: IMRN) announces a Live Virtual Event featuring positive Phase 2 Travelan results and upcoming Phase 3 clinical trials. The event will showcase the company's success in developing oral immunotherapeutics for gut-mediated diseases, with significant reductions in diarrhea cases and promising revenue projections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
conferences
-
News
Immuron Travelan® sales continued strong growth
Rhea-AI Summary
Immuron (IMRN) reports significant sales growth for Travelan®, an immune supplement, in Australia and the USA. FYTD Mar 2024 sales reached AUD$3.6 million, up 154% from the prior year, with Australia leading at AUD$2.8 million, up 234%. Sales on Walmart.com have commenced. The company aims to expand brand awareness and distribution in North America.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
none
-
News
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
Rhea-AI Summary
Immuron Limited announces positive interim topline results for Travelan® in preventing moderate to severe diarrhea caused by ETEC. The Phase 2 study showed significant protective efficacy with a single daily dose, supported by funding from the U.S. Department of Defense. The study demonstrated a 36.4% protective efficacy against moderate to severe diarrhea and a 66.7% protective efficacy against severe diarrhea compared to the placebo group. Additionally, there was an 83.3% reduction in subjects needing early antibiotic treatment and a 100% reduction in subjects requiring IV fluids post challenge in the Travelan® group. The study also reported a 55.6% reduction in adverse events associated with the ETEC challenge in the Travelan® group. The Phase 2 study data supported the excellent safety and tolerability profile of Travelan®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
175.76%
Tags
clinical trial
News
Immuron Presentation Australian Biologics Festival 2024
Rhea-AI Summary
Immuron Limited announces the participation of their Research & Development Manager at the Australian Biologics Festival 2024, showcasing their innovative work in biopharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
none
-
News
Immuron achieves record Travelan® sales
Rhea-AI Summary
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announces record Travelan® sales in YTD Jan 2024, exceeding FY20 sales. Australian sales reached $2.1 million, USA sales at $0.6 million, and Canadian sales recommenced through McKesson.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.74%
Tags
none
-
News
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
Rhea-AI Summary
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced that their CEO, Steven Lydeamore, will be presenting at the Monsoon Communications Investor function in Sydney, Australia. The presentation slide deck is available on the company's website for public access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
none
News
Immuron achieves record half yearly Travelan® sales
Rhea-AI Summary
Immuron Limited (ASX: IMC; NASDAQ: IMRN) has reported record half yearly sales of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®, with total sales reaching A$2,355,580 in H1, FY24. This marks a significant increase of $1,771,932 compared to H1, FY23 sales and a 51% increase over pre-pandemic period H1, FY20 sales. Australian sales of Travelan® increased by 132% compared to H1, FY23, while USA sales saw a slight decrease of 6% compared to the pre-pandemic peak period H1, FY20. Despite this, the Amazon launch in the USA is progressing well, with sales already ahead of budget. The company anticipates strong sales growth closer to the peak spring/summer travel period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
none
-
News
Immuron Clinical Trials Update
Rhea-AI Summary
Immuron Limited (ASX: IMC; NASDAQ: IMRN) completes in-patient phase of US Naval Medical Research Command campylobacter clinical program, prepares for Pre-IND submission to the FDA, and progresses Travelan clinical study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
Rhea-AI Summary
Immuron Limited (IMC; IMRN) announces the initiation of a clinical trial by the US Naval Medical Research Command to evaluate the efficacy of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) infections. The study aims to prevent infectious diarrhea, a common illness among travelers and US troops deployed overseas. The estimated study completion date is June 2024, with headline results expected in 2H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
clinical trial
News
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
Rhea-AI Summary
Immuron Limited (IMC; IMRN) invites shareholders to attend an investor webinar 'Coffee Microcaps Morning Meeting' on November 30, 2023. CEO Steven Lydeamore will provide an update on the business and upcoming milestones, followed by a Q&A session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.7%
Tags
none
Stock IMRN logo
Immuron Limited

Nasdaq:IMRN

IMRN Rankings

#5278 Ranked by Market Cap
#3053 Ranked by Stock Gains
N/A Ranked by Dividends

IMRN Stock Data

15.64M
188.40M
0.12%
0.45%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Australia
Melbourne

About IMRN

immuron ltd is a publicly listed australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (nash) diabetes, colitis, arthritis, inflammatory bowel diseases (ibd), irritable bowel syndrome (ibs), liver fibrosis and other chronic disorders in which the immune system plays a key role in thier pathogenesis. these disorders represent areas of growing and unmet medical need, where oral targeted therapy drugs could offer significant advantages due to the lack of absorption and the high safety profile. immuron has one marketed product, which provides proof of concept for its oral immune technology platform, and a pipeline of products at various stages of cl